NaturalShrimp’s Amoebic Gill Disease Technology Completes Successful Phase-I Testing
POSTED: Jul, 21 2020
Dallas, TX – July 17, 2020 – Natural Shrimp, Inc. (OTCMKTS: SHMP), announced today that CSIRO, Australia’s national science agency, through its Agriculture and Food Aquaculture Research Team in Tasmania, Australia has successfully completed Phase-I in vitro testing of a new technology that has proven effective at killing Neoparamoeba perurans, the parasite which causes Amoebic Gill Disease (“AGD”) of Atlantic salmon. With Phase-I efficacy completed, CSIRO are now moving to Phase-II, which will focus on fish welfare during the experimental treatment.
Natural Shrimp is funding the CSIRO research on the AGD technology through its market development partnership with Hydrenesis, Inc. (“Hydrenesis”), the exclusive, worldwide commercialization agent for the AGD technology in the aquaculture market.
Natural Shrimp’s President/CEO, Gerald Easterling, said, “We are positioning Natural Shrimp to be the leading provider of technology solutions in the fish farming business and we believe that this AGD technology from Hydrenesis is going to be a game changer for the salmon industry.”
Hydrenesis’ Chairman, Bob Watson, added that “AGD is costing the salmon industry tens of millions of dollars a year and we are eagerly working with CSIRO and Natural Shrimp to complete testing and begin commercializing this technology.”
ABOUT NATURAL SHRIMP: NaturalShrimp, Inc. is a publicly traded aqua-tech Company, headquartered in Dallas, with production facilities located near San Antonio, Texas. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.
Forward Looking Statements
This press release contains “forward-looking statements.” The statements contained in this press release that are not purely historical are forward-looking statements. Forward-looking statements give the Company’s current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company’s control, and could cause the Company’s results to differ materially from those described. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements include statements regarding moving forward with executing the Company’s global growth strategy. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this press release and does not undertake any obligation to update any forward looking statements contained in this press release as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Important factors that could cause such differences include, but are not limited to the Risk Factors and other information set forth in the Company’s Annual Report on Form 10-K filed on June 29, 2019, and in our other filings with the U.S. Securities and Exchange Commission.
Hydrenesis, Inc., headquartered in Pompano Beach, FL, is a private technology commercialization company that partners with leading IP holders and industry insiders to commercialize innovative technologies in major industry sectors.
As Australia’s national science agency and innovation catalyst, CSIRO solves the greatest challenges through innovative science and technology. We work with organisations large and small, delivering world-leading research and development solutions to help their business innovate, improve and grow. With 5,000 experts, state-of-the-art facilities, and a global collaborative research network we bring together the best and brightest minds to drive strategic growth and overcome unique business challenges like no other. Driven to create and facilitate societal, environmental and economic impact, we work with organisations across all major sectors and at all stages of the innovation lifecycle from strategic advice and planning, research and development, through to commercialisation and funding. www.csiro.au
Contact: Paul Knopick
[email protected]
940.262.3584